For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol...

For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over
Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)

Percutaneous Coronary Intervention Will Retain Decision Resources' Clinical
Gold Standard for Stable Angina, According to a New Report from Decision
Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that surveyed cardiologists identify a therapy's effect on
mortality as the attribute that most influences their prescribing decisions in
coronary heart disease (stable angina). Clinical data and the opinions of
interviewed thought leaders indicate that current and emerging therapies have
no advantage in this attribute over carvedilol (GlaxoSmithKline's Coreg,
generics), the sales-leading agent in the market.

The new report entitled Coronary Heart Disease (Stable Angina): To Gain Share,
Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality
also finds that a therapy that reduces plaque volume more than Pfizer's
Lipitor/Sortis/Tahor at 18 months would earn a 28 percent patient share in
stable angina in the United States and a 37 percent patient share in Europe,
according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for stable
angina was percutaneous coronary intervention (PCI). Based on available data
and expert opinion, PCI will retain gold-standard status for stable angina in
2012 as surveyed physicians believe it to be the most efficacious therapy for
treating the symptoms of stable angina.

"Interestingly, surveyed physicians also indicate that Cardium Therapeutics'
gene therapy Generx has great potential in treating stable angina," said
Decision Resources Analyst Kate Sullivan, B.S. "However, experts we
interviewed believe gene therapy is still at least 10 years away from becoming
a viable therapeutic approach for the indication, which leaves PCI, over the
next decade, as the most efficacious therapy for providing symptom relief to
patients."

About the Report
Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must
Not Only Control Symptoms but Also Reduce Mortality is a DecisionBase 2009
report. DecisionBase 2009 is a decision-support tool that provides in-depth
analysis of unmet need, physician expectations of new therapies and commercial
dynamics to help pharmaceutical companies optimize their investments in drug
development.

The report can be purchased by contacting Decision Resources. Members of the
media may request an interview with an analyst.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
ccomfort@dresources.com emarshall@dresources.com

SOURCE Decision Resources

Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com